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ABSTRACT
Objective: Tubtim-chumphae rice is hybrid Thai rice with a red pericarp. This study was aimed to investigate the effect of Tubtim-chumphae rice bran 
on insulin resistance and intrahepatic fat accumulation in high-fat-high-fructose diet (HFFD) fed rats.
Methods: Ethanolic extract of rice bran (ERB) was prepared using a 50% ethanol-water. Male Sprague-Dawley rats were fed HFFD (40% lard, 20% 
fructose) for 10 weeks, followed by concomitant administrations of distilled water or ERB at 250 or 500 mg/kg/day or pioglitazone at 10 mg/kg/day 
for a further 4 weeks in treated groups. Normal control rats were fed normal chow and distilled water. At the end of all treatments, fasting blood 
glucose (FBG), an oral glucose tolerance test (OGTT), serum insulin levels, lipid profiles, and liver fat contents were measured. Liver histological and 
peroxisome proliferator-activated receptor-α (PPAR-α) gene expression examinations were performed.
Results: At week 14, control HFFD rats had significantly (p<0.05) higher FBG, low-density lipoprotein cholesterol, triglycerides, and insulin secretions 
together with impaired OGTT as compared to normal control rats. These parameters indicated an insulin resistant and dyslipidemic condition in HFFD 
rats. ERB 250 and 500 mg/kg or pioglitazone 10 mg/kg significantly ameliorated all of these changes. HFFD also caused a significant increase in fat 
accumulation and a decrease in PPAR-α gene expression in the livers which were significantly decreased by ERB.
Conclusions: ERB decreases insulin resistance and intrahepatic fat accumulation possibly through increasing PPAR-α gene expression in HFFD rats. 
ERB might possibly be a neutraceutical for the metabolic syndrome patients.
Keywords: Insulin resistance, Metabolic syndrome, Rice bran, Type 2 Diabetes.
INTRODUCTION
The metabolic syndrome is composed of several metabolic changes 
including insulin resistance, impaired glucose tolerance, dyslipidemia, 
and central obesity. These metabolic changes provoke a risk of major 
health problems such as cardiovascular disease, Type 2 diabetes 
(Type 2 DM), and nonalcoholic fatty liver disease (NAFLD) [1]. Insulin 
resistance is proposed to be the main etiology of metabolic changes [2]. 
Chronic and excessive intake of a high-calorie fat and sugar diet can 
cause insulin resistance and fat accumulation in the liver (steatosis) [3]. 
Intrahepatic fat accumulation is the early stage of NAFLD and is 
the result of a high-fat intake, de novo lipogenesis or released lipids 
from adipose tissue [4]. Fructose is a monosaccharide found in many 
fruits, vegetables, honey, and soft drinks. It has been shown that 
overconsumption of fructose can enhance the risk of insulin resistance 
because fructose is predominantly metabolized in the liver where it 
promotes de novo lipogenesis and very low-density lipoprotein (LDL) 
biogenesis, and eventually intrahepatic fat accumulation [5].
The general recommendations for treatment of metabolic disorders 
are lifestyle modifications, such as caloric restriction, healthy 
foods, increased physical activity, medicinal herbs or neutraceutical 
supplementations, and eventually pharmacological intervention [3]. 
Various types of rice (Oryza sativa) are widely cultivated around the 
world. Rice is not only a major source of energy but also a source of 
many bioactive compounds and especially antioxidants including 
phenolic compounds [6-8]. Rice bran, a byproduct of rice grain milling 
process, is also full of many valuable bioactive compounds such as 
Vitamin E, γ-oryzanol, and anthocyanins [9] with health beneficial 
effects in decreasing blood cholesterol and reducing the incidence of 
atherosclerotic disease [10]. Interestingly, we have previously shown 
that the hydrolysate of white rice bran could decrease blood glucose, 
decrease hyperinsulinemia, improve dyslipidemia, and decrease 
the expression levels of the proinflammatory genes tumor necrosis 
factor-alpha, Il-6, Nos2, and Mcp-1 in high-fat high-carbohydrate-
induced metabolic syndrome rats [11]. Those results indicated that 
the hydrolysate of white rice bran increases insulin sensitivity and 
improves metabolic changes in metabolic syndrome.
Tubtim-chumphae rice, a Thai rice cultivar RD69 with a red pericarp, is 
a hybrid of white Jasmine rice and colored Sangyod rice. This hybrid rice 
has a high content of phenolic compounds, Vitamin E (γ-tocopheral), 
and γ-oryzanol (www.Thairice.org). Thus, Tubtim-chumphae rice bran 
may be another source of nutraceuticals for persons with metabolic 
syndrome and also Type 2 D. However, it still lacks the experiment to 
prove the therapeutic effect of colored rice bran on insulin resistance 
and intrahepatic fat accumulation in insulin resistance animals. 
Therefore, the objective of this study was to investigate the effect of the 
ethanolic extract of Tubtim-chumphae rice bran on insulin resistance 
and intrahepatic fat accumulation as well as its molecular mechanism 
in high-fat-high-fructose diet (HFFD) induced insulin resistant rats.
METHODS
Chemicals
Pioglitazone (Piozone’s®, M&H Manufacturing Co. Ltd. Thailand), Trizol 
reagent and Diethyl pyrocarbonate-treated water (Invitrogen, San Diego, 
California), iScript Reverse Transcription Supermix for RT-q polymerase 
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chain reactions (PCR) and SsoFast EvaGreen Supermix with Low ROX 
(Bio-RAD, USA), Agarose (Vivantis Inc., USA), Rat/Mouse Insulin ELISA 
Kit (Millipore MA, USA), Reagent Kit for determinations of LDL, high-
density lipoprotein (HDL) and triglyceride (TG) (Wako Pure Chemical 
Industries, Ltd. Japan), Pentobarbital Sodium solution (Nembutal®, 
Ceva animal health., LTD., Thailand), sterile water for injection (A.N.B. 
Laboratories Co., LTD., Thailand), and normal saline solution (Thai 
Nakorn Patana Co., LTD., Thailand) were used in this study.
Rice bran material and extraction
Tubtim-chumphae rice bran (hybrid Thai rice cultivar RD69) was kindly 
supplied by Chumphae Rice Research Center, Chumphae district, Khon 
Kaen Province, Thailand. Preparation of the ethanolic extract of Tubtim-
chumphae rice bran (ERB) was used as follows: To inactivate endogenous 
lipases, rice bran was heated at 121°C for 15 min and dried in a cabinet 
drier at 60°C for 5 h. The oil component was squeezed out by a screw 
press. After that, the defatted rice bran powder (200 g) was soaked in 1 L 
of 50% ethanol for 1 day with continuous shaking and filtered through 
Whatman No. 1 filter paper. The filtrates from three soakings were 
pooled together, and the solvent was removed using a rotary evaporator 
under reduced pressure and 60°C. The extract was dried by a freeze-
drying process. The percent yield of this procedure is 10.4. The obtained 
powder Tubtim-chumphae ERB was stored at -20°C until used.
To characterize the extract, the type and amount of some phenolic 
compounds were analyzed using a reverse-phase column and 
a ultraviolet-vis diode array detector high-performance liquid 
chromatography-diode-array detection (HPLC-DAD)-based assay [12].
Animal and experimental groups
Male Sprague-Dawley rats (230–250 g body weight) were purchased 
from the Nomura Siam International Co., Ltd, Bangkok, Thailand. Rats 
were housed in the Northeast Laboratory Animal Center and were 
maintained at 12 h of light/dark cycles at 25±1°C, and fed with a 
standard chow diet (Perfect Companion Group Co. Ltd., Thailand) and 
drinking distilled water. Only the animals that were the induced insulin 
resistance group were fed a HFFD (HFFD of 40% lard and 20% fructose). 
All procedures complied with the standards for the care and use of 
experimental animals and approved by the Animal Ethics Committee 
of Khon Kaen University, Khon Kaen, Thailand (ACUC-KKU-17/2559).
After feeding the animals with a normal diet or HFFD for 10 weeks, the 
rats were divided into 6 groups with 6–8 animals each as follows: Group 1: 
Normal control group treated with distilled water, Group 2: Normal 
rats treated with ERB at a dose of 500 mg/kg BW/day, Group 3: HFFD 
rats treated with distilled water, Groups 4 and 5: HFFD rats treated 
with ERB at doses of 250 and 500 mg/kg BW/day, and Group 6: HFFD 
rats treated with pioglitazone at dose of 10 mg/kg BW/day. ERB was 
dissolved in distilled water. All treatments were administered orally 
daily to the animals for a further 4 weeks. During the additional 4 weeks 
of treatment, the animals continued to be fed HFFD for the HFFD groups. 
Fasting blood glucose (FBG) and oral glucose tolerance tests (OGTT) 
were determined before and after 4 weeks for all treatments. Serum 
insulin and lipid profiles were performed after treatments. The livers 
were collected at the end of this additional 4 weeks of each treatment for 
determining lipid content, peroxisome proliferator-activated receptor-α 
(PPAR-α) expression, and histological examination.
Determination of FBG, OGTT, lipid profile, and insulin
Rats were fasted overnight (10–12 h), and blood samples were taken 
from the lateral tail vein to examine the FBG using a glucometer (Accu-
check Advantage II; Roche, Germany). Then, the animals were orally 
administered glucose at 2.0 g/kg [13] to evaluate OGTT. The blood 
glucose concentrations after glucose loading at 30, 90, and 120 min were 
determined. An area under the curve (AUC) of blood glucose-time (from 
0 to 120 min) was calculated. The fasting sera were also used to measure 
LDL, HDL, and TG using the Wako® diagnostics reagent (Wako, Japan), 
and insulin using the Rat/Mouse Insulin ELISA Kit (Millipore MA, USA). 
The assay was performed according to the manufacturer’s protocol.
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is 
one index of insulin resistance which is calculated as follows: (Fasting 
insulin [μIU/mL] X fasting glucose [mmol/L])/22.5 [14]. Insulin 
1 μIU/mL is equal to 6.945 pmol/L.
Determination of fat in liver and histological examination
The hepatic TG was examined as described by Naowaboot [15]. 
Briefly, 50 mg of liver was homogenized, and dissolved in 1 mL of 
isopropanol. Then, it was centrifuged at 10,000 rpm for 15 min at 4°C. 
The supernatant was collected. The TG contents of the analyzed liver 
samples were determined using the Wako Assay kit for TG. The amount 
of hepatic TG was expressed as mg/g tissue.
A portion of liver was fixed in buffered neutral formalin (10%) and 
the fixed tissue was processed for paraffin embedding. Tissue sections 
were stained with hematoxylin and eosin. Microscopic histological 
examinations of liver were performed.
Determination of liver PPAR-α gene expression
Total RNA was extracted from frozen liver tissues by TRIzol® reagents 
according to the manufacturer’s instructions. 1 mg of total RNA was 
then reverse transcribed to single-stranded cDNA using iScript reverse 
transcriptase (Bio-Rad, Hercules, CA). PCR were carried out using specific 
primers as follows: b-actin forward 5’-GGAGATTACTGCCCTGGCTCCTA-3’ 
and b-actin reverse 5’-GACTCATCG TACTCCTGCTTGCTG-3’, PPAR-α 
forward 5’-CTGGAGCCTAACGGACAGGTC-3’ and PPAR-α reverse 
5’-ACACTGCCGCAGCTAAGACTT-3’. The reaction was performed with 
SsoFastTM EvaGreen Supermix with low Rox (Bio-Rad, Hercules, CA) using 
Light Cycler 480II/384 (Roche Applied Science) under the following 
conditions: Denaturation at 95°C for 3 min and amplification by cycling 
40 times at 95°C for 15 s and 60°C for 31 s. The relative expression ratio 
of the target gene was calculated compared to the reference b-actin gene.
Statistical analysis
All results are presented as mean±SEM. The effects of ERB on blood 
glucose, OGTT, serum lipid profile, liver TG, serum insulin, and expression 
of PPAR-α were analyzed by analysis of variance followed by Student 
Newman–Keuls tests to show specific group differences. The level 
of significance was uniformly set at p<0.05. Statistical analyses were 
carried out using Statistical Package for the Social Sciences version 19.
RESULTS
Characteristic of ERB
Using a HPLC-DAD based assay, gallic acid, catechin, and isoquercetin 
were found at high amounts of 214.12, 212.60, and 201.64 mg/kg, 
respectively. Tannic acid, rutin, quercetin, and apigenin were found at 
the amounts of 189.92, 156.37, 113.13, and 6.12 mg/kg, respectively. 
Eriodictyol, kaempferol, and hydroquinone were not detectable at a 
5 mg/kg limit of detection.
Effect of ERB on body weight gaining
The body weights at the starting point of all experimental groups were 
similar (range 230–270 g). Feeding HFFD for the first 10 weeks did not 
affect the weight of the animals, however, continued feeding for a further 
4 weeks caused a significant increase in body weight (Table 1). The HFFD 
rats that received ERB (250 or 500 mg/kg) in the past 4 weeks had both 
lower body weights and growth rates (% increase in body weight) as 
compared to the control HFFD group receiving distilled water (Table 1). 
Pioglitazone (10 mg/kg) did not show body weight reduction.
Effect of ERB on FBG and OGTT
At the end of week 10 of HFFD feeding, the average of FBG of each group 
was in the range of 82–88 mg/dL, which was not significantly different 
from normal diet fed rats. The OGTT results, however, showed that the 
AUC of blood glucose from 0 to 120 min (AUC showing the amount 
of glucose in blood from 0 min to 120 min) of HFFD fed animals was 
significantly higher than that of normal control rats; this indicated 
an impairment of glucose tolerance and possibly an insulin resistant 
situation. Continued feeding with HFFD for a further 4 weeks caused 
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a significantly high FBG and AUC as compared to normal diet fed rats 
(Table 2). This indicated that the hyperglycemia and insulin resistance 
occurred in rats fed with HFFD for 14 weeks. Interestingly, the HFFD 
rats treated with ERB (250 and 500 mg/kg) or pioglitazone, had 
significantly lower FBG and AUC values than that of HFFD control rats 
(Table 2) indicating that ERB or pioglitazone could decrease FBG and 
improve OGTT in HFFD fed animals.
Effect of ERB on insulin secretion and HOMA-IR values
At the end of 14 weeks of HFFD feeding, the HFFD control rats had 
significant increases in serum insulin levels (6.34±1.37 ng/ml) and 
high HOMA-IR values (43.63±9.63) as compared to normal control 
animals (serum insulin; 1.34±0.38 ng/ml, HOMA-IR value; 5.78±1.47) 
which indicated insulin resistance in HFFD control animals (Fig. 1). 
ERB administration at 250 and 500 mg/kg caused significant decreases 
in insulin secretion (3.21±0.64 and 2.60±0.76 ng/ml) and HOMA-IR 
values (18.69±3.75 and 14.29±4.41). Pioglitazone also decreased both 
insulin and HOMA-IR levels (Fig. 1).
Effect of ERB on serum lipid profile and liver lipid content
HFFD feeding caused significant increases in serum cholesterol LDL 
and TG levels, and a significant decrease in HDL levels (Table 3) as 
compared to the normal control group which indicated a dyslipidemic 
situation in HFFD rats. Interestingly, the treatment with ERB at 250 and 
500 mg/kg significantly decreased the levels of LDL and TG but had no 
effect on the levels of HDL. Pioglitazone decreased LDL and TG and also 
increased HDL levels (Table 3).
Determination of intrahepatic fat showed that the HFFD control 
group had a significant fat deposition in the liver (107.20±3.59 mg/g 
tissue) as compared to the normal control group (41.88±8.76 mg/g 
tissue), Fig. 2. The liver fat content of the ERB rats of the 250 and 
500 mg/kg treated HFFD rats was significantly decreased (75.60±8.02 
and 68.14±5.97 mg/g tissue) as compared to that of HFFD control group 
(Fig. 2) which indicated that ERB could decrease fat accumulation in 
livers of animals fed HFFD. ERB at 500 mg/kg, however, did not affect 
fat accumulation in livers of normal rats. Pioglitazone also decreased fat 
deposition in liver (47.03±3.47 mg/g tissue), Fig. 2.
Histological examination of liver tissue was performed to confirm the 
effects of ERB on liver fat accumulation. It showed that hepatocytes of 
HFFD control rats prominently contained one or more large fat droplets 
and displaced the nuclei to eccentric positions (Fig. 3b), whereas the 
HFFD rats that received ERB or pioglitazone showed a mild deposition 
of fat (Fig. 3c, d, and e).
Effect of ERB on PPAR-α expression in liver
To examine the possible mechanisms of lipid-lowering activity and 
insulin resistance improvement activity of ERB, this study examined the 
effects of ERB on the expression of fatty acid beta-oxidation regulating 
the PPAR-α gene in liver cells using PCR technique. It was found that 
HFFD animals had lower expressions of PPAR-α mRNA (fold change of 
Table 1: Effect of ERB on body weight gaining of HFFD rats
Groups Body weight (g) % increases of 
body weightWeek 10 Week 14
Normal control 681.67±21.09 693.33±19.54 4.81±0.67
Normal+ERB 500 613.00±9.03 663.00±11.73 6.37±0.79
HFFD control 694.50±22.04 790.67±30.17* 12.22±0.90*
HFFD+ERB 250 685.33±40.08 694.83±38.03# 5.18±1.84#
HFFD+ERB 500 638.67±15.75 646.83±18.67# 4.67±1.66#
HFFD+Pio 10 683.60±10.52 806.20±17.73* 16.11±1.10*
HFFD: High-fat-high-fructose diet, ERB 250 or 500: Ethanolic extract of rice 
bran at 250 or 500 mg/kg, Pio 10: Pioglitazone at 10 mg/kg, *p<0.05 as 
compared with normal control, #p<0.05 as compared with HFFD control
Table 2: Effect of ERB on FBG and OGTT
Groups FBG (mg/dL) Area under curve (min.mg/dL)
Week 10 Week 14 Week 10 Week 14
Normal control 77.27±3.48 81.36±4.93 13353±191 13329±493
Normal+ERB 500 80.25±3.12 79.00±2.43 14565±67 13680±541
HFFD control 82.00±3.79 110.80±1.69* 16920±662* 17933±327*
HFFD+ERB 250 87.67±2.30 94.60±1.75# 15925±590* 15606±385#
HFFD+ERB 500 86.17±2.24 92.67±3.80# 15848±767* 15138±545#
HFFD+Pio 10 88.20±3.36 93.75±1.43# 16410±620* 13335±672#
HFFD: High-fat-high-fructose diet, ERB 250 or 500: Ethanolic extract of rice bran at 250 or 500 mg/kg, Pio 10: Pioglitazone 10 mg/kg, *p<0.05 as compared with normal 
control, #p<0.05 as compared with HFFD control, n=6–8, FBG: Fasting blood glucose, OGTT: Oral glucose tolerance test
Fig. 1: Effect of ethanolic extract of rice bran (ERB) on serum insulin (a) and Homeostasis Model Assessment of Insulin Resistance 
(HOMA-IR) scores (b) treatment of the high-fat-high-fructose diet (HFFD) rats with ERB at 250 and 500 mg/kg could significantly 
decrease the serum insulin levels and HOMA-IR scores. ERB, Pioglitazone 10 mg/kg, *p<0.05 as compared with normal control, #p<0.05 as 
compared with HFFD control
ba
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0.66±0.03) than that of normal control animals (Fig. 4). Treatment with 
ERB at 250 and 500 mg/kg or pioglitazone caused a significant increase 
in PPAR-α expression as compared to HFFD controls (fold changes of 
1.09±0.05, 0.80±0.02, and 0.81±0.07, respectively), Fig. 4.
DISCUSSION
After 14 weeks of HFFD feeding, the rats had an insulin resistant 
situation; impaired OGTT, hyperinsulinemia, high FBG, high LDL, and 
TG levels, together with an accumulation of fat in the livers. These 
results showed that ERB could ameliorate all those metabolic changes 
in HFFD-induced insulin resistant rats and ERB did not affect glucose 
and lipid metabolism in normal rats.
A HFFD has been used to induce insulin resistance in animals [16]. 
A high-fat diet has been known to induce insulin resistance in both 
humans and animal models. Excess calorie intake can theoretically be 
stored in adipose tissue, but as the inflammatory process increases 
and insulin resistance develops in the fat cells the ability to safely store 
excess fat is compromised. One of the consequences of insulin resistance 
in the adipose tissue is that excess fat is released into the bloodstream 
and is sequestered by other organs such as liver and skeletal muscles 
causing cellular lipotoxicity and finally insulin resistance in those 
organs [17]. It has been proposed that the lipid-overload causes a build-
up of diacylglycerides or free fatty acids or ceramides; these substances 
inhibit the intracellular signaling of insulin through serine/threonine 
phosphorylation of insulin receptor substrate-1 [18]. Fructose 
consumption has also been shown to enhance the risk of metabolic 
syndrome, including obesity, insulin resistance, and Type 2 D. Fructose 
is predominantly metabolized in the liver where it enhances de novo 
lipogenesis [5] probably resulting in enhanced insulin resistance.
Interestingly, for glucose metabolism, ERB decreased FBG and 
improved OGTT, and for lipid metabolism, ERB decreased LDL and TG 
levels in HFFD rats. In addition, ERB decreased hyperinsulinemia and 
the HOMA-IR score. All these beneficial changes indicate that ethanolic 
extract of Tubtim-chumphae rice bran could improve insulin resistance 
and may have antidiabetic activity. The obtained results correspond to 
an in vitro experiment reported by Boue [19]. They have reported an 
in vitro effect of ethanolic extract of colored rice bran cultivated in Brazil 
on glucose levels and insulin activity; inhibiting α-glucosidase activity, 
stimulating glucose uptake and increasing expression of Glucose 
transporter type (GLUT)1 and GLUT4 mRNA in 3T3-L1 adipocytes. The 
Table 3: Effect of ERB on serum lipid profile in HFFD rats
Groups Lipid profile (mg/dL)
LDL HDL TG
Normal control 11.92±1.21 31.67±1.79 74.00±10.46
Normal+ERB500 11.43±1.24 36.70±1.87 78.00±10.62
HFFD control 22.57±3.40* 21.55±2.38* 104.75±8.38*
HFFD+ERB 250 14.64±1.06# 27.82±3.62 49.50±6.94#
HFFD+ERB 500 11.31±1.03# 29.62±5.22 39.00±2.12#
HFFD+Pio 10 13.43±1.18# 38.64±5.46# 57.60±7.96#
HFFD: High-fat-high-fructose diet, ERB 250 or 500: Ethanolic extract of 
rice bran at 250 or 500 mg/kg, Pio 10: Pioglitazone 10 mg/kg, *p<0.05 as 
compared with normal control, #p<0.05 as compared with HFFD control, n=6–8, 
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, TG: Triglyceride
Fig. 2: Effects of ethanolic extract of rice bran (ERB) on hepatic 
fat accumulation. ERB at 250 and 500 mg/kg could significantly 
decrease the fat accumulation in liver. Pioglitazone 10 mg/kg, 
*p<0.05 as compared with normal control, #p<0.05 as compared 
with high-fat-high-fructose diet control
Fig. 3: Histological examination of liver tissue of (a) normal 
control, (b) high-fat-high-fructose diet (HFFD), (c, d) HFFD treated 
with ethanolic extract of rice bran (ERB) at 250 mg/kg and 
500 mg/kg; and (e) pioglitazone groups using light microscopy 
with a magnification of 40X. HFFD control rats contained one or 
more large fat droplets that prominently displaced the nucleus 
to an eccentric position, whereas the HFFD rats that received 
ethanolic ERB or pioglitazone (Pio) showed a mild deposition of 




Fig. 4: Effects of ethanolic extract of rice bran (ERB) on liver 
peroxisome proliferator-activated receptor-α (PPAR-α) 
expression in high-fat-high-fructose diet (HFFD) rats. ERB at 
250 and 500 mg/kg could significantly increase the PPAR-α 
expression in liver cells of HFFD rats. Pioglitazone 10 mg/kg, 
*p<0.05 as compared with normal controls, #p<0.05 as compared 
with HFFD control
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mechanism of anti-diabetic and insulin resistance improving activities 
of ERB will be further investigated in Type 2 D animals.
Fat and fructose overconsumption has also been reported to cause 
intrahepatic fat accumulation promoting the development of NAFLD 
that is linked with metabolic disorders such as obesity and Type 2 D [5]. 
Liver lipid accumulation or steatosis is the early stage of NAFLD which 
can occur from the diet, from de novo lipogenesis or lipids released from 
adipose tissue. It is a phenomenon that develops rapidly when rats are 
fed a high-fat diet, but the accumulation does not increase linearly over 
time [1]. In the case of a chronic high-fat diet; however, the concurrent 
oxidative stress, inflammatory processes, mitochondrial dysfunction, 
and insulin resistance may finally cause the hepatocyte injuries leading 
to steatohepatitis or cirrhosis which is the second stage of NAFLD. 
This study also found lipid accumulation in the livers of HFFD rats as 
well. Interestingly, the liver lipid content which was examined both 
by biochemical and histological Methods,. the results of these two 
methods were consistent showing that ERB treatment could decrease 
the accumulation of fat in the liver of HFFD rats. At the present state of 
knowledge, our report appears to be the first report demonstrating an in 
vivo anti-insulin resistance and intrahepatic fat decreasing activities of the 
ethanolic extract of defatted colored rice bran in insulin-resistant animals.
PPAR-α is a ligand-activated transcription factor regulating genes in 
controlling fat metabolism. Many PPAR-α target genes are involved 
in fatty acid metabolism including genes involved in mitochondrial 
β-oxidation, peroxisomal β-oxidation, fatty acid uptake and binding, 
and lipoprotein assembly, and transport in tissues such as muscle, 
heart, and liver [20]. PPAR-α activation has been reported to improve 
steatosis, inflammation, and fibrosis in animal models of non-alcoholic 
fatty liver disease [21]. As fatty acids or diacylglycerol or ceramides all 
are proposed to cause insulin resistance, and PPAR-α is transcription 
factor regulating gene in controlling fat metabolism, therefore further 
investigation of the effects of ERB on PPAR-α gene expression in liver 
was pursued. Interestingly, it was found that ERB could noticeably 
increase the expression of PPAR-α. Thus, it can be proposed that one of 
the possible mechanisms of action of ERB is that ERB increases PPAR-α 
expression resulting in a decrease of insulin resistance, LDL, and TG 
blood levels as well as fat accumulation in the liver. In the aspect of 
PPAR-α in regulating the body weight, it has been shown that PPAR-α 
agonists could reduce body weight and adiposity in animal models [22]. 
This probably may explain why the HFFD rats receiving ERB had lower 
body weights than those of control HFFD rats.
Pioglitazone is known to improve insulin sensitivity, glycemic control, 
dyslipidemia, hypertension, and microalbuminuria in patients with 
Type 2 D. Pioglitazone selectively stimulates the PPAR-γ and to a lesser 
extent PPAR-α [23]. It modulates the transcription of the genes involved 
in the control of glucose and lipid metabolism in the muscle, adipose 
tissue, and the liver. As a result, pioglitazone reduces insulin resistance 
in the liver and peripheral tissues, decreases gluconeogenesis in the 
liver, and reduces the levels of glucose and glycated hemoglobin in the 
bloodstream. This current study employed pioglitazone treatment as a 
positive control group in which pioglitazone showed effects as expected.
CONCLUSIONS
HFFD feeding for 14 weeks was found to cause insulin resistance and 
steatosis in rats. At the present state of knowledge, this is the first 
report demonstrated that the treatment with an ethanolic extract of 
colored rice bran can decrease insulin resistance and fat accumulation 
in liver through stimulation of PPAR-α expression in HFFD rats. Thus, of 
ERB Tubtim-chumphae may possibly be used as neutraceutical for the 
metabolic syndrome and Type 2 diabetic patients.
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